Humanigen, Inc. (HGEN) financial statements (2021 and earlier)

Company profile

Business Address 533 AIRPORT BLVD.
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:6891420001
Cash and cash equivalents6891420001
Other undisclosed cash, cash equivalents, and short-term investments    0  
Restricted cash and investments0   0  
Intangible current assets00     
Other undisclosed current assets0110000
Total current assets:6892420012
Noncurrent Assets
Restricted cash and investments0000000
Other undisclosed noncurrent assets00     
Total noncurrent assets:0000000
TOTAL ASSETS:6892430112
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1915119877
Accounts payable13926544
Accrued liabilities 694 44
Employee-related liabilities5   3  
Deferred revenue2      
Debt  04112
Due to related parties   22  
Other undisclosed current liabilities   0221
Total current liabilities:20151115141010
Noncurrent Liabilities
Long-term debt and lease obligation   11  
Long-term debt, excluding current maturities   11  
Liabilities, other than long-term debt2      
Deferred revenue2      
Other undisclosed noncurrent liabilities     33
Total noncurrent liabilities:2  1133
Total liabilities:23151117151312
Stockholders' equity
Stockholders' equity attributable to parent467732(16)(14)(13)(11)
Common stock0000000
Additional paid in capital420419343271270270270
Accumulated deficit(374)(342)(311)(287)(285)(283)(280)
Total stockholders' equity:467732(16)(14)(13)(11)
TOTAL LIABILITIES AND EQUITY:6892430112

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues0      
Operating expenses(33)(31)(23)(2)(2)(2)(3)
Other undisclosed operating income0      
Operating loss:(32)(31)(23)(2)(2)(2)(3)
Nonoperating expense
(Other Nonoperating expense)
 (0)     
Interest and debt expense (0)(1)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(32)(31)(24)(2)(2)(2)(3)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(32)(31)(24)(2)(2)(2)(3)
Comprehensive loss, net of tax, attributable to parent:(32)(31)(24)(2)(2)(2)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: